X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2362) 2362
Newsletter (155) 155
Publication (130) 130
Book Review (57) 57
Book Chapter (22) 22
Magazine Article (10) 10
Newspaper Article (10) 10
Conference Proceeding (6) 6
Dissertation (4) 4
Trade Publication Article (4) 4
Paper (2) 2
Data Set (1) 1
Journal / eJournal (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rivastigmine (2335) 2335
humans (1412) 1412
alzheimer's disease (920) 920
alzheimer disease - drug therapy (824) 824
male (803) 803
cholinesterase inhibitors - therapeutic use (780) 780
donepezil (772) 772
aged (763) 763
dementia (745) 745
female (726) 726
index medicus (724) 724
alzheimers-disease (551) 551
clinical neurology (494) 494
pharmacology & pharmacy (460) 460
aged, 80 and over (423) 423
psychiatry (421) 421
phenylcarbamates - therapeutic use (413) 413
galantamine (407) 407
treatment outcome (396) 396
double-blind (377) 377
middle aged (365) 365
neurosciences (359) 359
piperidines - therapeutic use (339) 339
indans - therapeutic use (337) 337
efficacy (325) 325
cholinesterase inhibitors (323) 323
geriatrics & gerontology (295) 295
phenylcarbamates (285) 285
cholinesterase inhibitors - adverse effects (257) 257
animals (256) 256
cholinesterase inhibitors - pharmacology (243) 243
drug therapy (239) 239
cholinesterase-inhibitors (229) 229
galantamine - therapeutic use (218) 218
memantine (214) 214
neuropsychological tests (214) 214
cholinesterase inhibitors - administration & dosage (213) 213
neuroprotective agents - therapeutic use (209) 209
carbamates - therapeutic use (204) 204
placebo-controlled trial (198) 198
research (193) 193
nootropic agents - therapeutic use (189) 189
acetylcholinesterase (184) 184
dementia - drug therapy (183) 183
phenylcarbamates - administration & dosage (178) 178
safety (175) 175
medicine, general & internal (167) 167
double-blind method (161) 161
activities of daily living (158) 158
phenylcarbamates - adverse effects (157) 157
alzheimer disease - psychology (155) 155
care and treatment (152) 152
parkinson's disease (151) 151
acetylcholinesterase inhibitors (149) 149
brain (145) 145
analysis (144) 144
diagnosis (144) 144
memantine - therapeutic use (144) 144
severity of illness index (143) 143
dose-response relationship, drug (140) 140
butyrylcholinesterase (137) 137
gerontology (135) 135
medical research (135) 135
cognition - drug effects (133) 133
cognition disorders - drug therapy (133) 133
alzheimers disease (132) 132
rats (131) 131
medicine, experimental (126) 126
transdermal patch (123) 123
cholinesterase inhibitor (120) 120
randomized controlled trials as topic (117) 117
time factors (116) 116
cognition (111) 111
dosage and administration (109) 109
cognitive impairment (108) 108
memory (107) 107
moderate (106) 106
alzheimer disease - diagnosis (104) 104
alzheimer’s disease (104) 104
tacrine (104) 104
alzheimer disease - physiopathology (103) 103
adult (101) 101
therapy (101) 101
acetylcholine (99) 99
neurology (99) 99
indans - adverse effects (98) 98
piperidines - adverse effects (98) 98
lewy bodies (97) 97
acetylcholinesterase - metabolism (94) 94
disease progression (94) 94
phenylcarbamates - pharmacology (94) 94
vascular dementia (92) 92
cognition disorders - etiology (90) 90
parkinson disease - drug therapy (90) 90
drugs (89) 89
retrospective studies (89) 89
parkinson disease - complications (88) 88
risk factors (88) 88
neuroprotective agents - administration & dosage (87) 87
prospective studies (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2306) 2306
German (77) 77
Spanish (45) 45
French (33) 33
Russian (23) 23
Dutch (22) 22
Japanese (19) 19
Chinese (10) 10
Portuguese (10) 10
Italian (6) 6
Turkish (3) 3
Czech (2) 2
Danish (2) 2
Norwegian (2) 2
Polish (2) 2
Croatian (1) 1
Finnish (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 01/2017, Volume 25, Issue 1, pp. 360 - 371
Journal Article
Zeitschrift fur Gerontologie und Geriatrie, ISSN 0948-6704, 10/2016, Volume 49, Issue 7, p. 662
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00391-016-1130-1 
Rivastigmine | Dementia
Journal Article
Neuroscience, ISSN 0306-4522, 07/2014, Volume 272, p. 116
acents Rivastigmine ameliorates depressive-like behaviors in olfactory bulbectomized mice. acents 5-HT.sub.1A receptor is involved in rivastigmine-induced... 
Rivastigmine | Depression, Mental
Journal Article
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 12/2017, Volume 141, pp. 232 - 239
Journal Article
Journal Article
European Psychiatry, ISSN 0924-9338, 03/2015, Volume 30, p. 1445
Rivastigmine is the only approved transdermal therapy for Alzheimer's disease (AD). Reduced drug concentration variability compared to oral formulations may... 
Rivastigmine | Alzheimer's disease
Journal Article
NEUROLOGY, ISSN 0028-3878, 07/2007, Volume 69, pp. S14 - S22
The rivastigmine patch is the first transdermal treatment for Alzheimer disease (AD). By providing continuous delivery of drug into the bloodstream over 24... 
RIVASTIGMINE | DEMENTIA | INVENTORY | EFFICACY | CLINICAL NEUROLOGY
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0182547
Objective To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment. Methods We recruited... 
NEUROCOGNITIVE IMPAIRMENT | THERAPY | TRAIL | MULTIDISCIPLINARY SCIENCES | EDUCATION | FLUENCY | BRAIN | AGE | Cognitive Dysfunction - drug therapy | Neuroprotective Agents - therapeutic use | Anti-Retroviral Agents - therapeutic use | Cognitive Dysfunction - virology | Rivastigmine - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Administration, Cutaneous | Cognitive Dysfunction - etiology | Neuropsychological Tests | Lithium - therapeutic use | Pilot Projects | Rivastigmine - administration & dosage | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | Rivastigmine - therapeutic use | Neuroprotective Agents - adverse effects | Neuroprotective Agents - administration & dosage | Executive Function - drug effects | Psychological aspects | Complications and side effects | Rivastigmine | Dosage and administration | Cognition disorders | Research | Drug therapy | HIV infection | Risk factors | Drugs | Antiretroviral drugs | Therapy | Executive function | Cognitive ability | Parkinsons disease | Impairment | Data processing | Lithium | Infections | Medical diagnosis | Antiretroviral therapy | Studies | Randomization | Hospitals | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Information processing | Neuropsychology | Trends | Safety | Dementia | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article